To resect or not to resect? Insight on managing the asymptomatic primary tumor in colorectal cancer patients with synchronous unresectable metastases from the prospective Japan Clinical Oncology Group Trial

Affiliations

Editorial

J Joshua Smith. Surgery. 2021 Dec.

. 2021 Dec;170(6):1856-1857.

doi: 10.1016/j.surg.2021.06.022. Epub 2021 Jul 16.

¹ Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: smithj5@mskcc.org.

No abstract available

Comment on

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Yamazaki K, et al. Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177863 Clinical Trial.